{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:41:33Z","timestamp":1783654893300,"version":"3.55.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Oslo University Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>New treatment modalities have not been widely adopted for patients with glioblastoma (GBM) after the addition of temozolomide to radiotherapy. We hypothesize that increased extent of resection (EOR) has resulted in improved survival for surgically treated patients with glioblastoma at the population level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective analysis of adult patients operated for glioblastoma in the population of South\u2013Eastern Norway. Patients were stratified into Pre-temozolomide- (2003\u20132005), temozolomide- (2006\u20132012), and resection-focused period (2013\u20132019) and evaluated according to age and EOR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 1657 adult patients operated on for supratentorial glioblastoma. The incidence of histologically confirmed glioblastoma increased from 3.7 in 2003 to 5.3 per 100 000 in 2019. The median survival was 11.4 months. Complete resection of contrast-enhancing tumor (CRCET) was achieved in 386 patients, and this fraction increased from 13% to 32% across the periods. Significant improvement in median survival was found between the first 2 periods and the last (10.5 and 10.6 vs. 12.3 months; P\u2005&amp;lt;\u2005.01), with a significant increase in 3- and 5-year survival probability to 12% and 6% (P\u2005&amp;lt;\u2005.01). Patients with CRCET survived longer than patients with non-CRCET (16.1 vs. 10.8 months; P\u2005&amp;lt;\u2005.001). The median survival doubled in patients\u2005\u226570 years and (12.1 months). Survival was similar between the time periods in patients where CRCET was achieved.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We demonstrate an improved survival of GBM patients at the population level associated with an increased fraction of patients with CRCET. The data support the importance of CRCET to improve glioblastoma patient outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npad037","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T10:38:20Z","timestamp":1688380700000},"page":"555-564","source":"Crossref","is-referenced-by-count":10,"title":["The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: A population-based study"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3582-8014","authenticated-orcid":false,"given":"Eduardo Erasmo","family":"Mendoza Mireles","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Oslo University Hospital , Oslo , Norway"},{"name":"Vilhelm Magnus Laboratory, Institute for Surgical Research, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-3492","authenticated-orcid":false,"given":"Erlend","family":"Skaga","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Oslo University Hospital , Oslo , Norway"},{"name":"Vilhelm Magnus Laboratory, Institute for Surgical Research, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-4527","authenticated-orcid":false,"given":"Andres","family":"Server","sequence":"additional","affiliation":[{"name":"Department of Radiology, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-8730","authenticated-orcid":false,"given":"Henning","family":"Leske","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-495X","authenticated-orcid":false,"given":"Petter","family":"Brandal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5758-6485","authenticated-orcid":false,"given":"Eirik","family":"Helseth","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Oslo University Hospital , Oslo , Norway"},{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-7415","authenticated-orcid":false,"given":"P\u00e5l A","family":"R\u00f8nning","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-4123","authenticated-orcid":false,"given":"Einar O","family":"Vik-Mo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Oslo University Hospital , Oslo , Norway"},{"name":"Vilhelm Magnus Laboratory, Institute for Surgical Research, Oslo University Hospital , Oslo , Norway"},{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"2023112317063023600_CIT0001","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"2023112317063023600_CIT0002","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"2023112317063023600_CIT0003","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3389\/fonc.2018.00462","article-title":"Developments in blood-brain barrier penetrance and drug repurposing for improved treatment of glioblastoma","volume":"8","author":"Harder","year":"2018","journal-title":"Front Oncol."},{"issue":"1","key":"2023112317063023600_CIT0004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clon.2016.09.015","article-title":"Radiotherapy in glioblastoma: The past, the present and the future","volume":"29","author":"Gzell","year":"2017","journal-title":"Clin Oncol"},{"issue":"3","key":"2023112317063023600_CIT0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg."},{"issue":"10","key":"2023112317063023600_CIT0006","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"4","key":"2023112317063023600_CIT0007","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: Current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br J Cancer."},{"issue":"6","key":"2023112317063023600_CIT0008","first-page":"1","article-title":"Biopsy versus resection for high-grade glioma","author":"Hart","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2023112317063023600_CIT0009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00701-013-1906-7","article-title":"5-ALA complete resections go beyond MR contrast enhancement: Shift corrected volumetric analysis of the extent of resection in surgery for glioblastoma","volume":"156","author":"Schucht","year":"2014","journal-title":"Acta Neurochir."},{"issue":"1","key":"2023112317063023600_CIT0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10143-017-0836-x","article-title":"The patients\u2019 view: Impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients\u2014results of a multicenter cross-sectional study","volume":"41","author":"Nickel","year":"2018","journal-title":"Neurosurg Rev."},{"key":"2023112317063023600_CIT0011","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.wneu.2017.04.041","article-title":"Extent of resection in glioma\u2013A review of the cutting edge","volume":"103","author":"D\u2019Amico","year":"2017","journal-title":"World Neurosurg"},{"issue":"11","key":"2023112317063023600_CIT0012","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis","volume":"2","author":"Brown","year":"2016","journal-title":"JAMA Oncol"},{"key":"2023112317063023600_CIT0013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2021.03.002","article-title":"Evidence-based recommendations on categories for extent of resection in diffuse glioma","volume":"149","author":"Karschnia","year":"2021","journal-title":"Eur J Cancer."},{"key":"2023112317063023600_CIT0014","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.wneu.2017.04.035","article-title":"Prognostic implications of extent of resection in glioblastoma: Analysis from a large database","volume":"103","author":"Trifiletti","year":"2017","journal-title":"World Neurosurg"},{"issue":"1","key":"2023112317063023600_CIT0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-0040-1701635","article-title":"Importance and evidence of extent of resection in glioblastoma","volume":"82","author":"Wykes","year":"2021","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"issue":"4","key":"2023112317063023600_CIT0016","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non\u2013contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol"},{"key":"2023112317063023600_CIT0017","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic health registry-based research: A review of health care systems and key registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"9","key":"2023112317063023600_CIT0018","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/neuonc\/nos153","article-title":"A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme","volume":"14","author":"R\u00f8nning","year":"2012","journal-title":"Neuro Oncol"},{"issue":"4","key":"2023112317063023600_CIT0019","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/ane.12966","article-title":"Improved survival of Swedish glioblastoma patients treated according to Stupp","volume":"138","author":"Bruhn","year":"2018","journal-title":"Acta Neurol Scand."},{"issue":"3","key":"2023112317063023600_CIT0020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/neuonc\/noy164","article-title":"Glioblastoma survival is improving despite increasing incidence rates: A nationwide study between 2000 and 2013 in Finland","volume":"21","author":"Korja","year":"2018","journal-title":"Neuro Oncol"},{"issue":"2","key":"2023112317063023600_CIT0021","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11060-018-2892-7","article-title":"Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014","volume":"139","author":"Hansen","year":"2018","journal-title":"J Neurooncol."},{"issue":"3","key":"2023112317063023600_CIT0022","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1600-0404.2010.01350.x","article-title":"Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme","volume":"122","author":"Helseth","year":"2010","journal-title":"Acta Neurol Scand."},{"issue":"2","key":"2023112317063023600_CIT0023","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-011-0749-4","article-title":"Glioblastoma survival in the United States before and during the temozolomide era","volume":"107","author":"Johnson","year":"2012","journal-title":"J Neurooncol."},{"issue":"2","key":"2023112317063023600_CIT0024","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/02688697.2014.967750","article-title":"Improvement in treatment results of glioblastoma over the last three decades and beneficial factors","volume":"29","author":"Kawano","year":"2015","journal-title":"Br J Neurosurg."},{"issue":"1","key":"2023112317063023600_CIT0025","first-page":"50","article-title":"Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: A Hong Kong population-level analysis over a 14-year period","volume":"10","author":"Woo","year":"2022","journal-title":"Neurooncol Pract"},{"key":"2023112317063023600_CIT0026","author":"SSB"},{"issue":"11","key":"2023112317063023600_CIT0027","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/bjc.2012.169","article-title":"Avoidable deaths and random variation in patients\u2019 survival","volume":"106","author":"Sepp\u00e4","year":"2012","journal-title":"Br J Cancer."},{"key":"2023112317063023600_CIT0028","author":"Human Mortality Database"},{"issue":"4","key":"2023112317063023600_CIT0029","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/1740774515586176","article-title":"Measures of follow-up in time-to-event studies: Why provide them and what should they be","volume":"12","author":"Betensky","year":"2015","journal-title":"Clin Trials"},{"issue":"4","key":"2023112317063023600_CIT0030","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.csda.2010.10.001","article-title":"Analyzing survival curves at a fixed point in time for paired and clustered right-censored data","volume":"55","author":"Su","year":"2011","journal-title":"Comput Stat Data Anal."},{"issue":"1","key":"2023112317063023600_CIT0031","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-007-9497-x","article-title":"Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: Case report","volume":"87","author":"Stummer","year":"2008","journal-title":"J Neurooncol."},{"issue":"5","key":"2023112317063023600_CIT0032","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group","volume":"25","author":"Karschnia","year":"2022","journal-title":"Neuro Oncol"},{"key":"2023112317063023600_CIT0033","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1227\/NEU.0b013e31826b2e75","article-title":"Does extent of resection of a glioblastoma matter","volume":"59","author":"Vogelbaum","year":"2012","journal-title":"Neurosurgery."},{"issue":"3","key":"2023112317063023600_CIT0034","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1006118018770","article-title":"Extent of resection as a prognostic variable in the treatment of gliomas","volume":"42","author":"Hess","year":"1999","journal-title":"J Neurooncol."},{"key":"2023112317063023600_CIT0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canep.2019.05.004","article-title":"Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway","volume":"61","author":"Nilssen","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"2023112317063023600_CIT0036","first-page":"50","article-title":"Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: A Hong Kong population-level analysis over a 14-year period","volume":"10","author":"Woo","year":"2023","journal-title":"Neurooncol Pract"},{"issue":"1","key":"2023112317063023600_CIT0037","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","article-title":"Improved survival time trends for glioblastoma using the SEER 17 population-based registries","volume":"107","author":"Koshy","year":"2012","journal-title":"J Neurooncol."},{"issue":"2","key":"2023112317063023600_CIT0038","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1227\/01.NEU.0000371990.86656.E8","article-title":"Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: A multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology)","volume":"67","author":"Scoccianti","year":"2010","journal-title":"Neurosurgery."},{"issue":"10","key":"2023112317063023600_CIT0039","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jocn.2015.03.032","article-title":"Patient and treatment factors associated with survival among adult glioblastoma patients: A USA population-based study from 2000\u20132010","volume":"22","author":"Pan","year":"2015","journal-title":"J Clin Neurosci."},{"issue":"3","key":"2023112317063023600_CIT0040","doi-asserted-by":"crossref","first-page":"e043208","DOI":"10.1136\/bmjopen-2020-043208","article-title":"Treatment approach and survival from glioblastoma: Results from a population-based retrospective cohort study from Western Norway","volume":"11","author":"Bjorland","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"2023112317063023600_CIT0041","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","article-title":"An extent of resection threshold for newly diagnosed glioblastomas: Clinical article","volume":"115","author":"Sanai","year":"2011","journal-title":"J Neurosurgery JNS"},{"issue":"4","key":"2023112317063023600_CIT0042","doi-asserted-by":"crossref","first-page":"E323","DOI":"10.1093\/neuros\/nyaa562","article-title":"MGMT-positive vs MGMT-negative patients with glioblastoma: Identification of prognostic factors and resection threshold","volume":"88","author":"Katsigiannis","year":"2021","journal-title":"Neurosurgery."},{"issue":"1","key":"2023112317063023600_CIT0043","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.wneu.2014.05.006","article-title":"How much is enough? the question of extent of resection in glioblastoma multiforme","volume":"82","author":"Abd-El-Barr","year":"2014","journal-title":"World Neurosurg"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npad037\/51327243\/npad037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/10\/6\/555\/53692600\/npad037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/10\/6\/555\/53692600\/npad037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T19:48:53Z","timestamp":1700768933000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/10\/6\/555\/7217016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,7,3]]},"published-print":{"date-parts":[[2023,11,23]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npad037","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,7,3]]}}}